# Mechanical Control of Coronary Angiogenesis in Myocardial Adaptation to Ischemia

> **NIH NIH R01** · NORTHEAST OHIO MEDICAL UNIVERSITY · 2020 · $437,160

## Abstract

Inadequate capillary growth; inadequate perfusion and the consequential ischemia can initiate the sequelae of
events causing the progression from an initial compensatory left ventricular hypertrophy (LVH) (in response to
hemodynamic challenge) to maladaptation leading to heart failure. Although pro-angiogenic strategies such as
delivery of growth factors and gene therapy are promising, there are limitations and concerns, including
delivery modalities, uncontrolled angiogenesis, limited half-life of growth factors, and effects on other organs.
Our proposal takes an alternative approach to test the hypothesis that mechanical forces in the hypertrophied
ventricle adversely affect coronary angiogenesis during heart failure. The central objective of this proposal is
to demonstrate that mechanical forces impede coronary angiogenesis during ischemia and hypertrophy. Our
objective is based on the counterintuitive observations that a) endothelial cells (EC) null for a
mechanosensitive ion channel, Transient Receptor Potential Vanilloid-4 (TRPV4) exhibited increased
proliferation, migration, Rho activity, and tube formation compared to wild type EC b) both ex vivo (aortic
sprouting) and in vivo (Matrigel, tumor and retinal) angiogenesis is enhanced in TRPV4KO mice compared
WT and c) global (TRPV4KO) or endothelial specific (TRPV4ECKO) TRPV4 knockout mice exhibited improved
cardiac function that correlated with reduced cardiac fibrosis and increased coronary angiogenesis compared
to WTs subjected to LVH induced by either myocardial infarction (MI) or pressure-overload (transverse aortic
constriction (TAC). These findings suggest that mechanical forces exert restraint on angiogenesis and
uncoupling this mechanical effect (endothelial TRPV4 mechanotransduction) restores angiogenesis and
cardiac function. Thus, our working hypothesis is that TRPV4 channels regulate angiogenesis via
modulation of Rho activity that regulates EC contraction and VEGFR2 trafficking via YAP and that the absence
of TRPV4 increases angiogenesis in myocardium and protects heart from ischemia- or pressure-overload-
induced cardiac injury. We will test this hypothesis in the following specific aims 1) To identify the structural
domains within TRPV4 that are required for the modulation of endothelial mechanosensitivity, Rho activation
and angiogenesis 2) To define the molecular mechanism(s) by which TRPV4 integrates Rho/YAP and VEGF
signaling in coronary angiogenesis and 3) To ascertain the functional significance of endothelial TRPV4 and to
target TRPV4 with a small molecule inhibitor to induce angiogenesis in the myocardium. To accomplish this,
we propose to use an innovative combination of advanced in vitro and in vivo techniques such as FRET,
contrast echocardiography, multi-photon microscopy, engineered ECM gels that mimic stiffness of heart,
endothelial-specific TRPV4KO mice (conventional and inducible) in conjunction with MI and TAC models. Our
proposed studies will provide insight...

## Key facts

- **NIH application ID:** 10019590
- **Project number:** 5R01HL148585-02
- **Recipient organization:** NORTHEAST OHIO MEDICAL UNIVERSITY
- **Principal Investigator:** Charles K Thodeti
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $437,160
- **Award type:** 5
- **Project period:** 2019-09-19 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10019590

## Citation

> US National Institutes of Health, RePORTER application 10019590, Mechanical Control of Coronary Angiogenesis in Myocardial Adaptation to Ischemia (5R01HL148585-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10019590. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*